Search 

Microbiotica is transforming personalised medicine with leading microbiome science, identifying gut bacteria linked to patient phenotype with unprecedented precision for the discovery of novel microbiome-based medicines and biomarkers of drug response.

Microbiotica was spun out of Trevor Lawley’s Lab at the Wellcome Sanger Institute and is founded on a unique pipeline for culturing and genomically characterising the entirety of the bacteria in the human gut for the first time. It has the world’s largest microbiome genome database and culture collection, a suite of translational in vitro and animal models, and state of the art bioinformatics and AI. The company has a focus on IBD and Immuno-Oncology, and a program in C. difficile which is spearheading innovation in development of live bacterial products.

Midatech Pharma is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines.
Driven by a team of scientists, engineers, and pharmaceutical development specialists, and led by an experienced management team, Midatech is progressing a pipeline of differentiated therapeutics in areas of high unmet need for the benefit of patients

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020).

The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type. The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.